McKesson Corporation (MCK) Stock: Price, Forecast & Analyst Target
McKesson Corporation (MCK) — MoonshotScore 92/100 (Exceptional band), calculated Nov 18, 2026. Price $1062.16 (-2.05%), as of the Nov 19, 2026 trading session; market cap $123B. Expected results Feb 3, 2027.
Educational signal · not a buy or sell recommendation · How to read this
McKesson Corporation · MCK · NYSE · Healthcare · Medical - Distribution
Research dated 2026-09-12: McKesson moves medicines and medical supplies through healthcare channels while also selling technology, access support and operating services to pharmacies, specialty practices and life-sciences companies. The case depends on whether rising distribution volume keeps producing more gross profit and cash despite the narrow economics of pharmaceutical wholesaling.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · McKesson (MCK)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet and elite growth, at a cheap price, though quality is only decent; the market is already moving on it. Business Quality: Solid; Financial Safety: Fortress; Valuation: Cheap; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Feb 3, 2027
- Altman Z 5.84 · Piotroski F 7
Helping: balance-sheet strength, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 92 | Exceptional | |
| 85 | Exceptional | |
| 92 | Exceptional | |
| 92 | Exceptional | |
| 92 | Exceptional | |
| 92 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1062.16 | |
| Change on the day | -2.05% | |
| 52-week range | $723.68–$1121.50 | |
| Market capitalisation | $123B | — |
| Price / earnings (trailing) | 27.96 | |
| Shares traded on the day | 611.6K | |
| Beta (volatility vs the S&P 500) | 0.28 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for McKesson (MCK): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is McKesson (MCK), and what does it report?
Short answer · as of
Most of McKesson’s revenue comes from distributing branded, generic, specialty, biosimilar and nonprescription medicines in North America.
Research dated 2026-09-12.
That makes reported sales largely a measure of product value moving through its network, while gross profit and operating profit better reveal the economic value retained by McKesson.
This is not merely a warehouse-and-delivery business. Oncology and multispecialty services, prescription access technology, pharmacy software and consulting, and medical-surgical logistics add service and technology economics around the distribution network, although pharmaceutical distribution remains dominant by revenue.
What do the latest results show for McKesson (MCK)?
Research dated 2026-09-12.
Revenue rebounded in the most recent reported period and exceeded the market estimate, while the reported earnings figure also cleared expectations. Gross profit did not share that sequential rebound, and operating profit, net income and statement earnings per share fell sharply from the preceding period.
The longer series is stronger than that snapshot: annual revenue and net income advanced, and recent reported earnings have generally exceeded estimates even when revenue did not. The mechanism to watch is the conversion of medicine volume into retained gross profit, because immense product throughput produces only a slim net margin.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $110.96B Nov 4, 2026
- Latest report · revenue estimate
- $109.90B Nov 4, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 4, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 4, 2026 | $110.96B | $109.90B | $11.6800 | $10.7200 |
| Aug 5, 2026 | $105.38B | $103.88B | $9.9300 | $9.5600 |
| May 7, 2026 | $96.30B | $101.35B | $11.6900 | $11.5600 |
| Feb 4, 2026 | $106.16B | $105.80B | $9.3400 | $9.1700 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $103.15B | $1.11B | $8.92 (diluted) |
| Q3 FY2026 | $106.16B | $1.19B | $9.59 (diluted) |
| Q4 FY2026 | $96.30B | $1.68B | $13.71 (diluted) |
| Q1 FY2027 | $105.38B | $614M | $5.15 (diluted) |
What are the financial strengths and risks for McKesson (MCK)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
McKesson remains profitable, its cash balance has risen across recent reporting periods, and the quality and distress screens are supportive. Cash nevertheless remains below total debt, current assets do not fully cover current liabilities under the reported ratio, and total liabilities are substantial.
Cash generation is lumpy rather than smoothly tracking earnings: operating cash flow turned negative in the latest period after a large positive result previously. With narrow gross, operating and net margins, weaker retained economics on pharmaceutical volume or higher operating costs can affect profit far more severely than the revenue line suggests.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 27.96 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at McKesson (MCK)?
Short answer · as of
The next earnings report is expected on Feb 3, 2027.
Research dated 2026-09-12.
Watch whether revenue growth again brings higher gross profit and whether operating profit recovers from its latest decline. Segment results should also reveal whether oncology and multispecialty services or prescription technology are becoming more meaningful beside the much larger pharmaceutical operation.
Cash conversion deserves equal attention. A return to positive operating cash flow, continued cash accumulation and restraint in debt would strengthen the financial picture; another disconnect between accounting profit and cash flow would make the recent volatility harder to dismiss. The scheduled earnings release provides the next checkpoint, while longer-range consensus assumes continued expansion in revenue and earnings.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does McKesson compare with its peers?
Short answer
McKesson's score ranks 2nd of 11 in the bounded comparison shown, against 10 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
McKesson’s defining feature is the combination of vast pharmaceutical throughput with services embedded deeper in medication delivery. Community oncology support, pharmacy technology, patient access and adherence tools, and medical-surgical logistics give it ways to earn around the medicine transaction that a plain wholesale description leaves out.
That mix does not change the financial signature of a distributor: revenue is enormous relative to the profit retained, and North American pharmaceutical distribution dominates segment sales. Comparison with similar businesses therefore belongs at the gross-profit, operating-profit and cash-conversion level, not on revenue scale alone.
| Company | Price | Market value | Score |
|---|---|---|---|
| $46.66 Nov 19, 2026 | $2.96B | 96 5-pillar Nov 18, 2026 | |
| McKesson (MCK) — this page | $1062.16 | $123B | 92 |
| $536.45 Nov 18, 2026 | $136B | 90 5-pillar Nov 18, 2026 | |
| $272.37 Nov 19, 2026 | $63.0B | 88 5-pillar Nov 18, 2026 | |
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| $341.25 Nov 19, 2026 | $65.1B | 86 5-pillar Nov 18, 2026 | |
| $58.34 Nov 19, 2026 | $119B | 85 5-pillar Nov 18, 2026 | |
| $80.06 Nov 19, 2026 | $102B | 81 5-pillar Nov 18, 2026 | |
| $48.58 Nov 18, 2026 | $97.4B | 77 5-pillar Nov 18, 2026 | |
| $84.80 Nov 19, 2026 | $9.37B | 73 5-pillar Nov 18, 2026 | |
| $49.60 Nov 19, 2026 | $2.35B | 63 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $845.00 – $1200.00
- Consensus target
- $998.57
- Median target
- $1000.00
Consensus record · Captured .
Measured against a quoted price of $1062.16 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026
- Transactions
- 30
- Identified insiders
- 18
- Purchases
- 0
- Sales
- 14
- Other transactions
- 16
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MCK in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.27% | $62.08M | Added +3.3% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about McKesson (MCK)?
What Investors Ask About McKesson (MCK) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does McKesson report enormous revenue but a thin net margin?
Most sales reflect medicines passing through McKesson’s distribution network. The company retains only a narrow portion as gross and operating profit, so revenue scale alone overstates the economics captured by shareholders.
How important is North American Pharmaceutical to McKesson?
North American Pharmaceutical dominates reported segment revenue and supplies branded, generic, specialty, biosimilar and nonprescription medicines. Its scale makes pharmaceutical volume and retained gross profit central to McKesson’s consolidated performance.
What does McKesson’s Prescription Technology Solutions business do?
Prescription Technology Solutions connects pharmacies, providers, payers and biopharmaceutical companies to support medication access and adherence. It also provides logistics and wholesale support, extending McKesson’s role beyond physical distribution.
Why should McKesson investors watch oncology and multispecialty services?
The business supports community specialty practices with technology, clinical guidance, practice tools and broader operating services. It is meaningful within the segment mix and offers service exposure alongside the much larger pharmaceutical distribution operation.
What is the MCK stock price today?
The last price recorded for McKesson Corporation (MCK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MCK price target?
The analyst consensus price target for McKesson Corporation (MCK), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 41 figures on this page — 1 from SEC filings and earnings calls, 34 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold MCK
Funds in our ETF coverage that list MCK among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Scharf ETF (KAT) | 6.13% | |
| SMI 3Fourteen Full-Cycle Trend ETF (FCTE) | 5.90% | |
| Texas Capital Texas Equity Index ETF (TXS) | 5.87% | |
| Amplify COWS Covered Call ETF (HCOW) | 3.10% | |
| Burney U.S. Equity Select ETF (BRES) | 2.51% | |
| SPCT ETF | 2.49% | |
| XHS ETF | 2.40% | |
| JPMorgan U.S. Minimum Volatility ETF (JMIN) | 0.70% | |
| T. Rowe Price Hedged Equity ETF (THEQ) | 0.40% |